Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase I study group trial of the Central European Society of Anticancer-Drug Research (CESAR)

MLA

Alberto Bernareggi, et al. “Phase I Clinical and Pharmacokinetic Study of BBR 3576, a Novel Aza-Anthrapyrazole, Administered i.v. Every 4 Weeks in Patients with Advanced Solid Tumors: A Phase I Study Group Trial of the Central European Society of Anticancer-Drug Research (CESAR).” Anti-Cancer Drugs, vol. 15, Jan. 2004, pp. 15–22. EBSCOhost, https://doi.org/10.1097/00001813-200401000-00003.

APA

Alberto Bernareggi, Angelika C. Stern, Heike Richly, Thomas Licht, Klaus Mross, Elena Verdi, Clemens Unger, Beatrice Vincenzi, Paola Barbieri, Klaus Kutz, Maria G. Camboni, & Max E. Scheulen. (2004). Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase I study group trial of the Central European Society of Anticancer-Drug Research (CESAR). Anti-Cancer Drugs, 15, 15–22. https://doi.org/10.1097/00001813-200401000-00003

Chicago

Alberto Bernareggi, Angelika C. Stern, Heike Richly, Thomas Licht, Klaus Mross, Elena Verdi, Clemens Unger, et al. 2004. “Phase I Clinical and Pharmacokinetic Study of BBR 3576, a Novel Aza-Anthrapyrazole, Administered i.v. Every 4 Weeks in Patients with Advanced Solid Tumors: A Phase I Study Group Trial of the Central European Society of Anticancer-Drug Research (CESAR).” Anti-Cancer Drugs 15 (January): 15–22. doi:10.1097/00001813-200401000-00003.